Biology of nuclear transcription factor NF-κB;Właściwości biologiczne czynnika transkrypcji ja̧drowej NF-κB

Alergia Astma Immunologia

Volumn 10, Issue 3, 2005, Pages 125-131

  Rutkowski, Ryszard ^a   Pancewicz, Sławomir Andrzej ^b   Skrzydlewska, Elzbieta ^c   Hermanowska Szpakowicz, Teresa ^b  

^a Akademii Medyczne   (Poland)

^b Klin Chorob Zakaznych/Neuroinfekcji   (Poland)

^c Zak ad Chemii Nieorganicznej i Analitycznej Uniwersytetu Medycznego   (Poland)

Author keywords

Activation pathways; Biological role; IKK; I B; NF B

Indexed keywords

HETERODIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; TRANSCRIPTION FACTOR RELA;

ARTICLE; FEEDBACK SYSTEM; GENE EXPRESSION; INFLAMMATION; PROTEIN PROTEIN INTERACTION;

EID: 33645341961     PISSN: 14273101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Yamamoto Y, Gaynor RB. IκB kinases: key regulators of the NF-κB pathway. Trends Biochem Sci 2004; 29: 72-79.
2. Li ZW, Rickert RC, Karin M. Genetic dissection of antigen receptor induced - NF-κB activation. Mol Immunol 2004; 41: 701-714.
3. Liou HCh, Hsia CY. Distinctions between c-Re1 and other NF-κB proteins in immunity and disease. BioEssays 2003; 25: 767-780.
4. Ruland J, Mak TW. From antigen to activation: specific signal transduction pathways linking antigen receptors to NF-κB. Semin Immunol 2003; 15: 177-183.
5. Jobin Ch, Sartor RB. The IκB/NF-κB system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000; 278: C451-C462.
6. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
7. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705-716.
8. Shapira S, Harb OS, Caamano J i wsp. The NF-κB signaling pathway: immune evasion and immunoregulation during toxoplasmosis. Int J Parasitol 2004; 34: 393-400.
9. Gruber BM. Czynnik transkrypcjny NF-κB - nowa perspektywa w leczeniu nowotworów. Post Biochem 2004; 50: 118-130.
10. Siednienko J, Gorczyca WA. Regulacja aktywności NF-κB. Post Hig Med Dosw 2003; 57: 19-32.
11. Rutkowski R, Moniuszko T, Rutkowski K. Nuclear Factor-kappa B (NF-κB). Ann Univ M C Skłodowska, Lublin-Polonia, Sectio D, 2002; 58 suppl. 9: 91-100.
12. Baldwin AS. The transcription factor NF-κB and human disease. J Clin Invest 2001; 107: 3-6.
13. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-288.
14. Hatada EN, Krappmann D, Scheidereit C. NF-κB and the innate immune response. Curr Opin Immunol 2000; 12: 52-58.
15. May MJ, Ghosh S. Signal transduction through NF-κB. Rev Immunol Today 1998; 19: 80-88.
16. Lee JI, Burckart GJ. Nuclear Factor kappa B: important transcriptional factor and therapeutic target. J Clin Pharmacol 1998; 38: 981-993.
17. Hultmark D. Drosophila immunity: paths and patterns. Curr Opin Immunol 2003; 15: 12-19.
18. Khush RS, Leulier F, Lemaitre B. Drosophila immunity: two paths to NF-κB. Trends Immunol 2001; 22: 260-264.
19. Silverman N, Zhou R, Stoven S i wsp. Drosophila IκB kinase complex required for relish cleavage and antibacterial immunity. Genes Dev 2000; 14: 2461-2471.
20. Meng X, Khanuja BS, Ip YT. Toll receptor-mediated Drosophila immune response requires Dif, an NF-κB factor. Genes Dev 1998; 13: 792-797.
21. Belvin MP, Anderson KV. A conserved signalling pathway: the Drosophila Toll-Dorsal pathway. Annu Rev Cell Biol 1996; 12: 393-416.
22. Perkins ND. The Rel/NF-κB family: friend or foe. TIBS 2000; 25: 434-440.
23. Gosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002; 109: 881-896.
24. Schoonbroodt S, Piete J. Oxidative stress interference with the Nuclear Factor - κB activation pathways. Biochem Pharmacol 2000; 60: 1075-1083.
25. Baldwin AS. The NF-κ and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-662.
26. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between Nuclear Factor - κB and steroid receptor-signaling pathway. Endocrinol Rev 1999; 20: 435-459.
27. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquination: the control of NF-κB activity. Annu Rev Immunol 2000; 18: 621-663.
28. Rothwarf DM, Karin M. The NF-κB activation pathway: a paradigm in information transfer from membrane to nucleus. Science Stke 1999; 1-16, www.stke.org.
29. Blackwell TS, Christman JW. The role of Nuclear Factor-κB in cytokine gene regulation. Am J Respir Cell Mol Biol 1997; 17: 3-9.
30. Rahman I, MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998; 53: 601-612.
31. Cogswell PC, Kashatus DF, Keifer JA i wsp. NF-κB and IκBα are found in the mitochondria. J Biol Chem 2003; 278: 2963-2968.
32. Bottero V, Rossi F, Samson M i wsp. IκBα, the NF-κB inhibitory subunit, interacts with ANT, the mitochondrial ATP/ADP translocator. J Biol Chem 2001; 276: 21317-221324.
33. Chen F, Castranova V, Shi X. New insights into the role of Nuclear Factor-κB in cell growth regulation. Am J Pathol 2001; 159: 387-397.
34. Yamazaki S, Muta T, Takeshige K. A novel IκB protein, IκB-ζ, induced by proinflammatory stimuli, negatively regulates Nuclear Factor-κB in the nuclei. J Biol Chem 2001; 276: 27657-27662.
35. Li N, Karin M. Is NF-κB the sensor of oxidative stress? FASEB J 1999; 13: 1137-1143.
36. Whiteside ST, Epinat JCh, Rice NR, Israel A. I kappa B epsilon, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J 1997; 16: 1413-1426.
37. Neurath MF, Becker C, Barbulescu K.: Role of NF-κB in immune and inflammatory responses in the gut. Gut 1998; 43: 856-860.
38. Simeonidis S, Stauber D, Chen G i wsp. Mechanism by which IκB proteins control NF-κB activity. Proc Natl Acad Sci USA 1999; 96: 49-54.
39. Cheng JD, Ryseck RP, Attar RM. Functional redundancy of the Nuclear factor κB inhibitiors IκBα and IκBβ. J Exp Med 1998; 188: 1055-1062.
40. Malek S, Chen Y, Huxford T, Ghosh G. IκBβ, but not IκBα functions as a classical cytoplasmatic inhibitor of NF-κB dimmers by masking both NF-κB nuclear localisation sequences in resting cells. J Biol Chem 2001; 276: 45225-45235.
41. Wardle EN. Nuclear factor κB for the nephrologist. Nephrol Dial Transplant 2001; 16: 1764-1768.
42. Fenwick C, Na SY, Voll RE i wsp. A subclass of Ras proteins that regulate the degradation of IκB. Science 2000; 287: 869-873.
43. Chen Y, Wu J, Gosh G. κB-Ras binds to the unique insert within the ankyrin repeat domain of IκB and regulates cytoplasmic retention of IκBβ:NF-κB complexes. J Biol Chem 2003; 278: 23101-23106.
44. Huang TT, Miyamoto S. Postrepression activation of NF-κB requires the amino-terminal nuclear export signal specific to IκBα. Mol Cell Biol 2001; 21: 4737-4747.
45. Karin M. The beginning of the end: IκB Kinase (IKK) and NF-κB activation. J Biol Chem 1999; 274: 27339-27342.
46. Kochel I, Strza̧dała L. Rola białek wia̧ża̧cych FK506 w regulacji aktywnosci czynnikow transkrypcyjnych w komorkach T. Post Hig Med Dośw 2004; 58: 118-127.
47. Huang TT, Kudo N, Yoshida M i wsp. A nuclear export signal in the N-terminal regulatory domain of IκBα controls cytoplasmic localization of inactive NF-κB/IκBα complexes. Proc Natl Acad Sci USA 2000; 97: 1014-1019.
48. Krappmann D, Wegener E, Sunami Y i wsp. The IκB kinase complex and NF-κB act as master regulators of lipopolysaccharide - induced gene expression and control subordinate activation of AP-1. Mol Cell Biol 2004; 24: 6488-6500.
49. Gerondakis S, Strasser A. The role of Rel/NF-κB transcription factors in B lymphocyte survival. Semin Immunol 2003; 15, 159-166.
50. Hayden MS, Gosh S. Signaling to NF-κB. Genes Dev 2004; 18: 2195-2224.
51. Makris C, Roberts JL, Karin M. The carboxyl-terminal region of IκB kinase γ(IKKγ) is required for full IKK activation. Mol Cell Biol 2002; 22: 6573-6581.
52. Verma IM, Stevenson J. IκB kinase: beginning not the end. Proc Natl Acad Sci USA 1997; 94: 11758-11760.
53. Zandi E, Rothwarf DM, Delhase M i wsp. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 1977; 91: 243-252.
54. May MJ, Larsen SE, Shim JH i wsp. A novel ubiquitin-like domain in IκB kinase β is required for functional activity of the kinase. J Biol Chem 2004; 279: 45528-45539.
55. Chen F, Castranova V, Shi X, Deemrs LM. New insights into the role of Nuclear Factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem. 1999; 45: 7-17.
56. Zandi E, Karin M. Bridging the gap: composition, regulation, and physiological function of the IκB kinase complex. Mol Cell Biol 1999; 19: 4547-4551.
57. Hofmann JA, Kafatos FC, Janeway ChA. Phylogenetic perspectives in innate immunity. Science 1999; 284: 1313-1318.
58. Hu WH, Mo XM, Walters WM i wsp. TNAP, a novel repressor of NF-κB-inducing kinase, suppresses NF-κB activation. J Biol Chem 2004; 279: 35975-35983.
59. Derudder E, Dejardin E, Pritchard LL i wsp. RelB/p50 dinners are differentially regulated by Tumor Necrosis Factor-α and Lymphotoxin-β receptor activation. J Biol Chem 2003; 278: 23278-23284.
60. Weih F, Caamano J. Regulation of secondary lymphoid organ development by the nuclear factor-κB signal transduction pathway. Immunol Rev 2003; 195: 91-105.
61. Yilmaz ZB, Weigh DS, Sivakumar V, Weih F. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J 2003; 22: 121-13.
62. Gugasyan R, Grumont R, Grossman M i wsp. Rel/NF-κB transcription factors: key mediators of B-cell activation. Immunol Rev 2000; 176: 134-140.
63. Klement JF, Rice NR, Abbondanzo SJ i wsp. IκBα deficiency results in a sustained NF-κB responses and severe widespread dermatitis in mice. Mol Cell Biol 1996; 16: 2341-2349.
64. Li Q, Lu Q, Hwang JY i wsp. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 1999; 13: 1322-1328.
65. Rudolph D, Yeh WCh, Wakeham A i wsp. Severe liver degeneration and lack of NF-κB activation in NEMO/IKKγ-deficient mice. Genes Dev 2000; 14: 854-862.
66. Christman JW, Sadikot RT, Blackwell TS. Nuclear Factor-κB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998; 24: 1131-1138.
67. Amit S, Ben-Neriah Y. NF-κB activation in cancer: a challenge for ubiquitination - and proteosome - based therapeutic approach. Semin Cancer Biol 2003; 13: 15-28.
68. Kowalski ML, Alam R. Signal transduction mechanisms as a new targets for allergists. Allergy 2001; 56: 199-203.
69. Orange JS, Levy O, Geha RS. Human disease resulting from gene mutations that interfere with appropriate Nuclear Factor-κB activation. Immunol Rev 2005; 203: 21-37.